Zydus Lifesciences shares climb over 4% as net profit rises 3% YoY to ₹1,467 crore in Q1; revenue up 5.9%

Shares of Zydus Lifesciences rallied 4.12% to an intra-day high of ₹995 apiece on the National Stock Exchange (NSE) on Wednesday, August 13, a day after reporting its June quarter results for the 2025-26 financial year (Q1FY26).

The pharma company’s consolidated net profit increased 3% year-on-year (YoY) to ₹1,467 crore in the first quarter of FY26, riding on strong performance across domestic and international markets. The drug maker has posted a net profit of ₹1,420 crore in the June quarter of the previous fiscal year.

Its revenue from operations rose 5.91% YoY to ₹6,574 crore during the quarter under review, compared to ₹6,207 crore in the year-ago period, the drug maker said in a statement.

The drug maker said its domestic business revenue increased 6% YoY to ₹2,374 crore during the reporting quarter, compared to ₹2,243.9 crore. Its revenue from the formulations business saw a growth of 8% YoY to ₹1,519 crore in Q1FY26, as against ₹1,407.3 crore in the year-ago period.

The company’s consumer wellness business revenue grew 2% YoY to ₹855 crore in the first quarter ended June 30, 2025. Its US formulations business revenue grew 3% YoY to ₹3,182 crore in the June quarter.

At an operational level, its EBITDA (earnings before interest, tax, depreciation and amortisation) remained stable at ₹2,089 crore. Its EBITDA margin shrank 200 basis points to 31.8% in Q1FY26, as against 29.6% in the first quarter of FY25.

Commenting on the earnings, Sharvil Patel, Managing Director of Zydus Lifesciences, said: “Our Q1 FY2026 performance reflects the results of our disciplined execution, with most of our key businesses meeting expectations. We remain firmly on track to achieve our FY2026 aspirations and are excited about the upcoming developments on the innovation front, which we believe will open up new avenues for sustainable growth.”

“As we pursue these opportunities, we continue to keep the highest standards of compliance at the core of all our operations, while building strong future growth pillars that will strengthen our position globally,” Patel added.

Zydus Lifesciences’ stock was trading 8.71% higher at ₹991.15 per equity share at around 1:33 pm.

The pharmaceutical has a total market capitalisation of ₹99,768.10 crore, as of August 13, 2025, as per data on the NSE.